Intravenous administration of irinotecan elevates the blood β- glucuronidase activity in rats

Cancer Research

Volumn 57, Issue 23, 1997, Pages 5305-5308

  Kaneda, Norimasa ^a   Kurita, Akinobu ^a   Hosokawa, Yukiko ^a   Yokokura, Teruo ^a   Awazu, Shoji ^b  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BETA GLUCURONIDASE; GLUCURONIDE; IRINOTECAN; KAMPO; PHENOLPHTHALEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME RELEASE; ENZYME SUBSTRATE; INTESTINE FLORA; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONIDASE; INJECTIONS, INTRAVENOUS; KINETICS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030719938     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kaneda, N., Nagata, H., Furuta, T., and Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
2. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51: 4187-4191, 1991.
3. Tsuji, T., Kaneda, N., Kado, K., Yokokura, T., Yoshimoto, T., and Tsuru, D. CPT-11 converting enzyme from rat serum: purification and some properties. J. Pharmacobio-Dyn., 14: 341-349, 1991.
4. Satoh, T., Hosokawa, M., Atsumi, R., Suzuki, W., Hakusi, H., and Nagai, E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharm. Bull., 17: 662-664, 1994.
5. Rivory, L. P., Bowles, M. R., Robert, J., and Pond, S. M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol., 52: 1103-1111, 1996.
6. Atsumi, R., Suzuki, W., and Hakusui, H. Identification of the metabolites of irinotecan, a new derivative camptothecin, in rat bile and its biliary excretion. Xenobiotica, 21: 1159-1169, 1991.
7. Satoh, T., Maki, T., Kobayashi, S., and Hosokawa, M. Multiplicity and toxicological implications of liver microsomal carboxylesterase. In: E. Hodgson, R. M. Roe, and N. Motoyama (eds.), Pesticides and Future: Toxicological Studies of Risk and Benefit, pp. 137-148. Raleigh, NC: North Carolina State University, 1991.
8. Medda, S., Stevens, A. M., and Swank, R. T. Involvement of the esterase active site of egasyn in compartmentalization of β-glucuronidase within the endoplasmic reticulum. Cell, 50: 301-310, 1987.
9. Keadtisuke, S., and Nakatsugawa, T. Significance of phosphorylation in organophosphate-mediated β-glucuronidase release from the rat liver. Pestic. Biochem. Physiol., 73: 213-219, 1980.
10. Leng, X-F., and Nakatsugawa, T. Paraoxon-induced release of β-glucuronidase from rat hepatocytes in vitro. Pestic. Biochem. Physiol., 21: 207-212, 1984.
11. Narita, M., Nagai, E., Hagiwara, H., Aburada, M., Yokoi, T., and Kamataki, T. Inhibition of β-glucuronidase by natural glucuronides of Kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica, 23: 5-10, 1993.
12. Yokoi, T., Narita, M., Nagai, E., Hagiwara, H., Aburada, M., and Kamataki, T. Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in Kampo medicines using SN-38 as a substrate. Jpn. J. Cancer Res., 86: 985-989, 1995.
13. Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., and Kamataki, T. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res., 56: 3752-3757, 1996.
14. Kaneda, N., and Yokokura, T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res., 50: 1721-1725, 1990.
15. Hosokawa, M., Maki, T., and Satoh, T. Multiplicity and regulation of hepatic microsomal carboxylesterases in rats. Mol. Pharmacol., 31: 579-584, 1987.
16. Heymann, E., and Mentlein, R. Carboxylesterases-amidases. In: W. B. Jakoby (ed.), Methods in Enzymology, Vol. 77, Detoxification and Drug Metabolism: Conjugation and Related Systems, pp. 333-344. New York: Academic Press, 1981.
17. Medda, S., Deimling, O. V., and Swank, R. T. Identity of esterase-22 and egasyn, the protein which complexes with microsomal β-glucuronidase. Biochem. Genet., 24: 229-243, 1986.
18. Medda, S., Takeuchi, K., Devore-Carter, D., Deimling, O. V., Heymann, E., and Swank, R. T. An accessory protein identical to mouse egasyn is complexed with rat microsomal β-glucuronidase and is identical to rat esterase-3. J. Biol. Chem., 262: 7248-7253, 1987.
19. Li, H., Takeuchi, K. H., Manly, K., Chapman, V., and Swank, R. T. The propeptide of β-glucuronidase. Further evidence of its involvement in compartmentalization of β-glucuronidase and sequence similarity with portions of the reactive site region of the serpin superfamily. J. Biol. Chem., 265: 14732-14735, 1990.
20. Medda, S., and Swank, R. T. Egasyn, a protein which determines the subcellular distribution of β-glucuronidase, has esterase activity. J. Biol. Chem., 260: 15802-15808, 1985.
21. de Forni, M., Bugat, R., Chabot, G. G., Culine, S., Extra, J-M., Gouyette, A., Madelaine, I., Marty, M. E., and Mathieu-Boué, A. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res., 54: 4347-4354, 1994.
22. Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T-L., Rock, M. K., and Donehower, R. C. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-hydroxy-[4-(piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res., 54: 427-436, 1994.
23. Canal, P., Gay, C., Dezeuze, A., Douillard, J. Y., Bugat, R., Brunet, R., Adenis, A., Herait, P., Lokiec, F., and Mathieu-Boue, A. Pharmacokinetics and pharmacodynamics of irinotecan during a Phase II clinical trial in colorectal cancer. J. Clin. Oncol., 14: 2688-2695, 1996.
24. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Yokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
25. Schaaf, L., Ichhpurani, N., Elfring, G., Wolf, D., Rothenberg, M., and Von Hoff, D. Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer. Proc. Am. Soc. Clin. Oncol., 16: 202a, 1997.